{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:23:13Z","timestamp":1778548993559,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The phase II, exploratory, open-label Exploring Nilotinib BCR-ABL Effects (ENABL) study [ ClinicalTrials.gov identifier: NCT00644878] assessed the impact of switching to nilotinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) who had a suboptimal molecular response with imatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with CML-CP who had previously achieved a complete cytogenetic response (CCyR), but had a suboptimal molecular response, with frontline imatinib therapy ( N = 18) were assigned to receive nilotinib 300 mg twice daily. The primary endpoint was the change in BCR-ABL1 transcript levels from baseline after 12 months; rates of major molecular response (MMR) and safety were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At 3 months after switching to nilotinib, 10 of 17 (59%) evaluable patients had achieved MMR. At 12 months, 9 of 12 (75%) evaluable patients had achieved MMR, and the median BCR-ABL1 level among all patients remaining in the study was 0.020% on the International Scale (IS), equivalent to a 3.7-log reduction from the standardized IS baseline (primary endpoint). Adverse events (AEs) were typically grade 1\/2 and manageable with dose interruptions. A total of three patients experienced serious study drug-related AEs, including pancreatitis, bradycardia, and vertigo. No deaths were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Overall, results from this exploratory study suggest that switching to nilotinib due to suboptimal molecular response with imatinib can result in improved molecular response for patients with CML-CP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2040620716678118","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T20:40:33Z","timestamp":1480106433000},"page":"3-12","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib"],"prefix":"10.1177","volume":"8","author":[{"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke P.","family":"Akard","sequence":"additional","affiliation":[{"name":"Department of Hematology, Indiana Blood and Marrow Transplantation, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole B.","family":"Miller","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine and Medical Oncology, St. Agnes Hospital, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Jillella","sequence":"additional","affiliation":[{"name":"Department of Medicine, Georgia Regents University, Augusta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solveig G.","family":"Ericson","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Lin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam","family":"Warsi","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[{"name":"Clinical Cancer Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"key":"bibr1-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"bibr2-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"bibr3-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2139"},{"issue":"2","key":"bibr4-2040620716678118","first-page":"292","volume":"96","author":"Goh H.","year":"2011","journal-title":"Haematologica"},{"key":"bibr5-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"bibr6-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"bibr7-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"bibr8-2040620716678118","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091272"},{"key":"bibr9-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544015"},{"key":"bibr10-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"bibr11-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2574"},{"key":"bibr12-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152"},{"key":"bibr13-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"bibr14-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"bibr15-2040620716678118","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0","author":"National Cancer Institute","year":"2006"},{"key":"bibr16-2040620716678118","unstructured":"National Comprehensive Cancer Network (2016) NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Available at: www.nccn.org."},{"key":"bibr17-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"bibr18-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403033"},{"key":"bibr19-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1112"},{"key":"bibr20-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4406"},{"key":"bibr21-2040620716678118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173674"},{"key":"bibr22-2040620716678118","unstructured":"US National Institutes of Health (2015) Study of molecular response in adult patients on nilotinib with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase and a suboptimal molecular response to imatinib (MACS0254). Available at: http:\/\/clinicaltrials.gov\/show\/NCT00644878."},{"key":"bibr23-2040620716678118","first-page":"235","volume":"91","author":"Wang L.","year":"2006","journal-title":"Haematologica"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620716678118","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2040620716678118","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620716678118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:13:49Z","timestamp":1777590829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2040620716678118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1177\/2040620716678118"],"URL":"https:\/\/doi.org\/10.1177\/2040620716678118","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,25]]}}}